Table 4.
Univariate and multivariate analysis of OS and PFS for patients with unresectable HCC.
| Variables | OS | PFS | ||||
|---|---|---|---|---|---|---|
| HR | 95%CI | P value | HR | 95%CI | P value | |
| Univariate analysis | ||||||
| Sex (Female/Male) | 1.395 | 0.610-3.189 | 0.430 | 1.326 | 0.665-2.645 | 0.423 |
| Age, year, (≤60, >60) | 1.964 | 0.939-4.109 | 0.073 | 0.746 | 0.375-1.485 | 0.404 |
| ALBI grade (1/2) | 1.615 | 0.831-3.139 | 0.158 | 1.241 | 0.705-2.184 | 0.454 |
| Antivirus therapy (No/Yes) | 0.906 | 0.478-1.716 | 0.762 | 1.390 | 0.816-2.366 | 0.225 |
| CA19-9, μg/L (≤39/>39) | 0.824 | 0.363-1.869 | 0.643 | 1.049 | 0.540-2.037 | 0.887 |
| CEA, μg/L (≤10/>10) | 0.927 | 0.222-3.870 | 0.917 | 0.657 | 0.159-2.706 | 0.561 |
| AFP, μg/L (≤20/>20) | 1.931 | 0.913-4.081 | 0.085 | 1.130 | 0.645-1.979 | 0.670 |
| PIVKA-II, μg/L (≤37/>37) | 1.009 | 0.444-2.292 | 0.984 | 0.798 | 0.417-1.527 | 0.495 |
| Child-Pugh (A/B) | 3.099 | 0.947-10.139 | 0.061 | 1.603 | 0.498-5.161 | 0.429 |
| HBsAg (Negative/Positive) | 0.842 | 0.353-2.011 | 0.699 | 1.151 | 0.540-2.452 | 0.715 |
| HBV-DNA load, IU/ml (≤2000/>2000) | 0.495 | 0.227-1.076 | 0.076 | 0.722 | 0.408-1.277 | 0.263 |
| Liver cirrhosis (No/Yes) | 1.144 | 0.604-2.168 | 0.680 | 1.355 | 0.787-2.331 | 0.273 |
| Extrahepatic metastasis (No/Yes) | 0.741 | 0.358-1.536 | 0.421 | 1.036 | 0.563-1.906 | 0.910 |
| Lymph node metastasis (No/Yes) | 0.509 | 0.156-1.655 | 0.261 | 1.154 | 0.519-2.562 | 0.726 |
| Macr0vascular invasion (No/Yes) | 1.091 | 0.522-2.280 | 0.817 | 1.028 | 0.556-1.899 | 0.931 |
| Tumor number (Single/Multiple) | 2.204 | 1.104-4.399 | 0.025 | 1.595 | 0.910-2.795 | 0.103 |
| Maximum tumor size, cm, (≤3, 3~5, >5) | 1.519 | 0.981-2.354 | 0.061 | 1.140 | 0.813-1.600 | 0.447 |
| Combined with PD-1(No/Yes) | 0.911 | 0.483-1.720 | 0.774 | 1.189 | 0.693-2.039 | 0.530 |
| Combined with radiotherapy (No/Yes) | 0.700 | 0.341-1.436 | 0.331 | 0.677 | 0.374-1.227 | 0.199 |
| Combined with TACE (No/Yes) | 1.096 | 0.457-2.628 | 0.837 | 1.147 | 0.538-2.443 | 0.723 |
| Lenvatinib ± PD-1vs. lenvatinib ± PD-1+ TACE ± radiotherapy | 1.065 | 0.646-1.757 | 0.805 | 0.705 | 0.476-1.045 | 0.082 |
| BCLC (A/B/C) | 1.102 | 0.717-1.693 | 0.657 | 1.338 | 0.916-1.955 | 0.132 |
| CNLC stage (Ia-Ib/IIa-IIb/IIIa-IIIb) | 1.052 | 0.700-1.582 | 0.806 | 1.240 | 0.864-1.780 | 0.243 |
| Multivariate analysis | ||||||
| Tumor number (Single/Multiple) | 2.204 | 1.104-4.399 | 0.025 | |||
HCC, hepatocellular carcinoma; OS, overall survival; PFS, progression-free survival; ALBI, Albumin-bilirubin grade; AFP, alpha-fetoprotein; PIVKA-II, Protein Induced by Vitamin K Absence or Antagonist-II; CA19-9, carbohydrate antigen 19-9; CEA, carcino-embryonic antigen; HBsAg, hepatitis B surface antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; BCLC, Barcelona Clinic Liver Cancer; CNLC, China liver cancer staging; TACE, transcatheter arterial chemoembolization. P<0.05 was defined as statistical significance (italicized and bold).